Skip to main content
NASDAQ:BRKR

Bruker Competitors

$66.45
-2.70 (-3.90 %)
(As of 05/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$66.31
$68.98
50-Day Range
$60.68
$70.03
52-Week Range
$36.82
$71.28
Volume501,796 shs
Average Volume466,424 shs
Market Capitalization$10.07 billion
P/E Ratio65.15
Dividend Yield0.23%
Beta1.29

Competitors

Bruker (NASDAQ:BRKR) Vs. TMO, ILMN, A, MTD, WAT, and BIO

Should you be buying BRKR stock or one of its competitors? Companies in the sub-industry of "life sciences tools & services" are considered alternatives and competitors to Bruker, including Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), and Bio-Rad Laboratories (BIO).

Thermo Fisher Scientific (NYSE:TMO) and Bruker (NASDAQ:BRKR) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation.

Risk and Volatility

Thermo Fisher Scientific has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Bruker has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500.

Institutional and Insider Ownership

87.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 65.9% of Bruker shares are held by institutional investors. 0.4% of Thermo Fisher Scientific shares are held by company insiders. Comparatively, 26.8% of Bruker shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Thermo Fisher Scientific and Bruker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Thermo Fisher Scientific17.12%21.35%10.55%
Bruker8.04%21.78%6.99%

Dividends

Thermo Fisher Scientific pays an annual dividend of $1.04 per share and has a dividend yield of 0.2%. Bruker pays an annual dividend of $0.16 per share and has a dividend yield of 0.2%. Thermo Fisher Scientific pays out 8.4% of its earnings in the form of a dividend. Bruker pays out 10.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Thermo Fisher Scientific has increased its dividend for 3 consecutive years and Bruker has increased its dividend for 1 consecutive years.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Thermo Fisher Scientific and Bruker, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Thermo Fisher Scientific021802.90
Bruker14302.25

Thermo Fisher Scientific presently has a consensus target price of $536.8947, indicating a potential upside of 18.06%. Bruker has a consensus target price of $62.00, indicating a potential downside of 6.70%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, analysts plainly believe Thermo Fisher Scientific is more favorable than Bruker.

Valuation & Earnings

This table compares Thermo Fisher Scientific and Bruker's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$25.54 billion7.00$3.70 billion$12.3536.82
Bruker$2.07 billion4.86$197.20 million$1.5742.32

Thermo Fisher Scientific has higher revenue and earnings than Bruker. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Bruker, indicating that it is currently the more affordable of the two stocks.

Summary

Thermo Fisher Scientific beats Bruker on 12 of the 17 factors compared between the two stocks.

Bruker (NASDAQ:BRKR) and Illumina (NASDAQ:ILMN) are both large-cap computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.

Risk & Volatility

Bruker has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500.

Institutional and Insider Ownership

65.9% of Bruker shares are owned by institutional investors. Comparatively, 90.0% of Illumina shares are owned by institutional investors. 26.8% of Bruker shares are owned by company insiders. Comparatively, 0.4% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Bruker and Illumina's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bruker8.04%21.78%6.99%
Illumina19.70%15.93%10.09%

Analyst Ratings

This is a summary of current ratings and recommmendations for Bruker and Illumina, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bruker14302.25
Illumina47602.12

Bruker presently has a consensus price target of $62.00, indicating a potential downside of 6.70%. Illumina has a consensus price target of $374.50, indicating a potential upside of 0.45%. Given Illumina's higher possible upside, analysts plainly believe Illumina is more favorable than Bruker.

Earnings & Valuation

This table compares Bruker and Illumina's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bruker$2.07 billion4.86$197.20 million$1.5742.32
Illumina$3.54 billion15.36$1.00 billion$6.5756.75

Illumina has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Summary

Illumina beats Bruker on 10 of the 14 factors compared between the two stocks.

Bruker (NASDAQ:BRKR) and Agilent Technologies (NYSE:A) are both large-cap computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.

Profitability

This table compares Bruker and Agilent Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bruker8.04%21.78%6.99%
Agilent Technologies13.47%21.02%10.73%

Risk & Volatility

Bruker has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Bruker and Agilent Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bruker14302.25
Agilent Technologies061902.76

Bruker presently has a consensus price target of $62.00, indicating a potential downside of 6.70%. Agilent Technologies has a consensus price target of $107.4350, indicating a potential downside of 16.48%. Given Bruker's higher possible upside, equities analysts plainly believe Bruker is more favorable than Agilent Technologies.

Earnings & Valuation

This table compares Bruker and Agilent Technologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bruker$2.07 billion4.86$197.20 million$1.5742.32
Agilent Technologies$5.34 billion7.34$719 million$3.2839.22

Agilent Technologies has higher revenue and earnings than Bruker. Agilent Technologies is trading at a lower price-to-earnings ratio than Bruker, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

65.9% of Bruker shares are owned by institutional investors. 26.8% of Bruker shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dividends

Bruker pays an annual dividend of $0.16 per share and has a dividend yield of 0.2%. Agilent Technologies pays an annual dividend of $0.78 per share and has a dividend yield of 0.6%. Bruker pays out 10.2% of its earnings in the form of a dividend. Agilent Technologies pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bruker has raised its dividend for 1 consecutive years and Agilent Technologies has raised its dividend for 1 consecutive years.

Summary

Agilent Technologies beats Bruker on 9 of the 16 factors compared between the two stocks.

Mettler-Toledo International (NYSE:MTD) and Bruker (NASDAQ:BRKR) are both large-cap computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.

Institutional and Insider Ownership

93.2% of Mettler-Toledo International shares are held by institutional investors. Comparatively, 65.9% of Bruker shares are held by institutional investors. 3.2% of Mettler-Toledo International shares are held by insiders. Comparatively, 26.8% of Bruker shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Mettler-Toledo International and Bruker's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mettler-Toledo International$3.01 billion9.60$561.11 million$22.7754.52
Bruker$2.07 billion4.86$197.20 million$1.5742.32

Mettler-Toledo International has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Mettler-Toledo International has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Bruker has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Mettler-Toledo International and Bruker, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mettler-Toledo International23101.83
Bruker14302.25

Mettler-Toledo International presently has a consensus price target of $1,048.3333, indicating a potential downside of 15.56%. Bruker has a consensus price target of $62.00, indicating a potential downside of 6.70%. Given Bruker's stronger consensus rating and higher possible upside, analysts clearly believe Bruker is more favorable than Mettler-Toledo International.

Profitability

This table compares Mettler-Toledo International and Bruker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mettler-Toledo International19.36%144.89%21.11%
Bruker8.04%21.78%6.99%

Summary

Mettler-Toledo International beats Bruker on 8 of the 14 factors compared between the two stocks.

Bruker (NASDAQ:BRKR) and Waters (NYSE:WAT) are both large-cap computer and technology companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Insider and Institutional Ownership

65.9% of Bruker shares are held by institutional investors. Comparatively, 91.8% of Waters shares are held by institutional investors. 26.8% of Bruker shares are held by company insiders. Comparatively, 1.5% of Waters shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Bruker and Waters' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bruker$2.07 billion4.86$197.20 million$1.5742.32
Waters$2.41 billion7.78$592.20 million$8.9933.78

Waters has higher revenue and earnings than Bruker. Waters is trading at a lower price-to-earnings ratio than Bruker, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Bruker has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Waters has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Bruker and Waters, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bruker14302.25
Waters37101.82

Bruker presently has a consensus price target of $62.00, suggesting a potential downside of 6.70%. Waters has a consensus price target of $251.25, suggesting a potential downside of 17.25%. Given Bruker's stronger consensus rating and higher possible upside, equities analysts plainly believe Bruker is more favorable than Waters.

Profitability

This table compares Bruker and Waters' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bruker8.04%21.78%6.99%
Waters22.61%-349.31%21.11%

Bruker (NASDAQ:BRKR) and Bio-Rad Laboratories (NYSE:BIO) are both large-cap computer and technology companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Insider and Institutional Ownership

65.9% of Bruker shares are held by institutional investors. Comparatively, 63.0% of Bio-Rad Laboratories shares are held by institutional investors. 26.8% of Bruker shares are held by company insiders. Comparatively, 27.5% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Bruker and Bio-Rad Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bruker$2.07 billion4.86$197.20 million$1.5742.32
Bio-Rad Laboratories$2.31 billion7.52$1.76 billion$7.0682.70

Bio-Rad Laboratories has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Bruker has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Bruker and Bio-Rad Laboratories, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bruker14302.25
Bio-Rad Laboratories00303.00

Bruker presently has a consensus price target of $62.00, suggesting a potential downside of 6.70%. Bio-Rad Laboratories has a consensus price target of $700.00, suggesting a potential upside of 19.89%. Given Bio-Rad Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Bruker.

Profitability

This table compares Bruker and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bruker8.04%21.78%6.99%
Bio-Rad Laboratories147.91%3.77%2.74%

Summary

Bio-Rad Laboratories beats Bruker on 8 of the 13 factors compared between the two stocks.


Bruker Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Thermo Fisher Scientific logo
TMO
Thermo Fisher Scientific
2.3$454.78-2.0%$178.74 billion$25.54 billion37.28Insider Selling
Analyst Revision
Illumina logo
ILMN
Illumina
1.6$372.84-2.3%$54.43 billion$3.54 billion86.51
Agilent Technologies logo
A
Agilent Technologies
1.8$128.64-2.2%$39.20 billion$5.34 billion55.93
Mettler-Toledo International logo
MTD
Mettler-Toledo International
1.3$1,241.45-0.1%$28.89 billion$3.01 billion52.23Earnings Announcement
Waters logo
WAT
Waters
1.3$303.64-4.0%$18.73 billion$2.41 billion37.81Analyst Report
Analyst Revision
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$583.89-2.1%$17.38 billion$2.31 billion5.00
Charles River Laboratories International logo
CRL
Charles River Laboratories International
1.3$316.76-1.2%$15.92 billion$2.62 billion52.79Insider Selling
High Trading Volume
Analyst Revision
Bio-Techne logo
TECH
Bio-Techne
1.8$408.88-1.6%$15.90 billion$738.69 million65.42Earnings Announcement
Dividend Announcement
PerkinElmer logo
PKI
PerkinElmer
1.9$137.86-1.1%$15.45 billion$2.88 billion37.46Analyst Revision
Pacific Biosciences of California logo
PACB
Pacific Biosciences of California
1.6$22.93-5.1%$4.55 billion$90.89 million-81.89Gap Down
Luminex logo
LMNX
Luminex
1.5$36.62-0.1%$1.73 billion$334.64 million93.90
Fluidigm logo
FLDM
Fluidigm
1.8$5.18-6.0%$388.31 million$117.24 million-7.73Earnings Announcement
Analyst Report
Gap Down
Harvard Bioscience logo
HBIO
Harvard Bioscience
1.8$6.95-0.9%$277.70 million$116.18 million-38.61Earnings Announcement
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.85-0.0%$61.64 million$420,000.00-1.45Analyst Report
News Coverage
This page was last updated on 5/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.